$INSM

Flammer Martina M.D. sold $193K of INSM

Flammer Martina M.D. (Chief Medical Officer) sold 1,858 shares of INSMED Inc (INSM) at $103.78 ($0.19M total) on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Flammer Martina M.D.
Published Jun 5, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSM
Neutral
medium confidence
Mentioned
$INSM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider liquidity/positioning but does not, by itself, signal a new company event.

02

Market read

Traders may monitor for incremental sentiment/flow effects, but the 10b5-1 structure limits fundamental inference.

03

What to watch

Look for other contemporaneous insider transactions (buys/sells) or changes in trading patterns around key clinical/regulatory milestones, which are not provided here.

Relevance 6/10Novelty 5/10Timing: Filed/dated 2026-06-05 (same day as the reported sale)

Background

This is an SEC Form 4 insider transaction: an officer (Chief Medical Officer) reported an open-market sale of INSM shares.

Company-level read

Ticker impact

$INSMNeutralMedium confidence
Context

INSMED CMO Martina Flammer sold $192.8K of INSM shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Low, likely limited to minor sentiment/flow effects; no clear directional signal from a 10b5-1 plan.

Evidence & confidence

The filing is an officer sale under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no disclosed operational/regulatory/clinical catalyst.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may not reflect bearish expectations; traders may discount it entirely.

Key entities

  • INSMED Inc

    Public company whose shares were sold by an officer under a 10b5-1 plan.

  • Flammer Martina M.D.

    Chief Medical Officer who sold 1,858 shares at $103.7800 on 2026-06-05.

Related articles

$INSMMed

Insmed Q2 Earnings Call Highlights

Insmed (INSM) reported Q2 call highlights. It narrowed BRINSUPRI gross-to-net guidance to mid-to-high 20% and raised global peak sales to over $7B. It expects ARIKAYCE expansion filings in the U.S. and Japan, with Japan application in 2H26. TPIP peak sales estimate rose to over $6B. Cash was about $1.2B; it targets cash-flow positivity in 2027.